`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`COSMO TECHNOLOGIES LIMITED,
`Patent Owner.
`
`
`Case IPR2017-01035
`
`Patent 9,320,716
`
`
`
`PETITIONER’S MOTION TO SEAL
`
`
`
`
`
`
`
`
`
`
`I.
`
`Introduction
`
`Pursuant to the Board’s authorization via email on July 7, 2017, Petitioner
`
`hereby moves to seal a few sentences of the Patent Owner’s Preliminary Response
`
`(“Preliminary Response”) (Paper 7) under 37 C.F.R. §§ 42.14 and 42.54. The
`
`information identified as confidential in this Motion has not been published or
`
`otherwise made public. The Parties have met and conferred and Patent Owner
`
`opposes this motion.1
`
`II. Legal Standard
`
`Under 35 U.S.C. § 316(a)(1), the default rule is that all papers filed in an
`
`inter partes review are open and available for access by the public and a party may
`
`file a motion to seal and that the information at issue is sealed pending the outcome
`
`of the motion. 37 C.F.R. § 42.14 provides that “[a] party intending a document or
`
`thing to be sealed shall file a motion to seal concurrent with the filing of the
`
`document or thing to be sealed.” The moving party has the burden of establishing
`
`“good cause” for sealing documents containing confidential information. Garmin
`
`Int’l, Inc. v. Cuozzo Speed Techs. LLC, IPR2012-00001, Paper 37 at 4 (PTAB,
`
`Apr. 5, 2013); see also 37 C.F.R. §§ 42.20(c), 42.54.
`
`
`1 Patent Owner also filed a public redacted Preliminary Response (Paper 8),
`
`which is the subject of Petitioner’s concurrently filed motion to expunge.
`
`
`
`
`1
`
`
`
`
`
`
`The Board’s rules identify confidential information in a manner consistent
`
`with Federal Rule of Civil Procedure 26(c)(1)(G), which provides for protective
`
`orders for trade secret or other confidential research, development, or commercial
`
`information. Office Patent Trial Practice Guide, 77 Fed. Reg. at 48,760; see also
`
`Illumina, Inc. v. Trustees of Columbia University in the City of New York,
`
`IPR2013-00011, Paper 66 at 6 (PTAB Aug. 12, 2013) (granting a motion to seal
`
`“technical and business information”).
`
`III.
`
`Identification of Confidential Information
`
`In this Motion to Seal, Petitioner requests limited portions of the Preliminary
`
`Response be sealed as “PROTECTIVE ORDER MATERIAL” under the Default
`
`Protective Order for revealing Petitioner’s confidential information pertaining to
`
`Petitioner’s ANDA product. Petitioner’s ANDA was filed confidentially with the
`
`Food and Drug Administration (“FDA) in order to obtain FDA approval to market
`
`a generic pharmaceutical product. No information from the ANDA has been made
`
`public by Petitioner or by the FDA, and it is not otherwise available to the public.
`
`Sandoz, Inc. v. EKR Therapeutics, LLC, IPR2015-00005, Paper 21 at 2 (PTAB
`
`Apr. 24, 2014) (sealing entire ANDA). Indeed, Patent Owner admits in its
`
`Preliminary Response that Petitioner has claimed that its ANDA information is
`
`confidential information, and that such information is subject to the District
`
`Court’s Protective Order. Preliminary Response at 6 fn. 3; Sandoz, Inc., IPR2015-
`
`
`
`
`2
`
`
`
`
`
`
`00005, Paper 21 at 3 (PTAB Apr. 24, 2014) (discussing relevance of considering
`
`the Protective Order in the Board’s determination).
`
`The following passages of the Preliminary Response contain confidential
`
`information that Petitioner seeks to redact:
`
`
`
`
`
`
`
`The portion of the sentence on page 6, footnote 2, the parenthetical at
`line 6 that is between the phrases “prove infringement” and “is
`nevertheless”;
`
`The portion of the sentence on page 36 lines 6-8 that is between the
`phrases “in district court litigation—” and “—should be rejected”; and
`
`The portion of the sentence on page 51 lines 9-11 that is between the
`phrases “in district court litigation—” and “—should be rejected.”
`
`The identified portions reveal confidential information regarding Petitioner’s
`
`ANDA product—specifically how the active ingredient in Petitioner’s ANDA
`
`product is distributed.
`
`IV. Good Cause Exists for Sealing the Confidential Information
`
`Petitioner requests that the above identified three (3) statements revealing
`
`confidential information about Petitioner’s ANDA product be sealed. Public
`
`disclosure of information regarding the arrangement of a component in Petitioner’s
`
`ANDA product, or how it is created/tested, would reveal confidential business
`
`information and is trade secret and/or confidential commercial information. It
`
`therefore qualifies as confidential information under 37 CFR § 42.2. Public
`
`disclosure of the information that Petitioner seeks to seal would be commercially
`
`harmful to Petitioner.
`
`
`
`
`3
`
`
`
`
`
`
`The Board has recognized such information, especially if it reveals
`
`information from the ANDA, should be protected from public disclosure. See
`
`Sandoz, Inc., IPR2015-00005, Paper 21 at 2 (PTAB Apr. 24, 2014) (sealing entire
`
`the ANDA); InnoPharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2015-
`
`00902, Paper 100 at 2-3 (PTAB Aug. 29, 2016) (sealing portions of the ANDA).
`
`Even though Patent Owner did not submit Petitioner’s ANDA itself as an
`
`exhibit, the assertions made by Patent Owner in its Preliminary Response with
`
`respect to the arrangement of a component in Petitioner’s ANDA product is based
`
`on information Patent Owner gained because it has access to Petitioner’s ANDA,
`
`and the related defenses being asserted by Petitioner, in the related District Court
`
`litigation. The information Petitioner seeks to seal is directly derived from
`
`Petitioner’s ANDA.
`
`In its Motion to Seal (Paper 9), Patent Owner asserts that the sole basis to
`
`seal the Preliminary Response is because it quotes Exhibit 2025, excerpts of a trial
`
`transcript from another district court litigation. Paper 9 at 3. Petitioner, however,
`
`was not a party to that other litigation and no information about Petitioner’s ANDA
`
`product was revealed in that litigation. Nevertheless, the Preliminary Response
`
`reveals information regarding Petitioner’s ANDA product. Tellingly, several of
`
`the redactions made by Patent Owner do not even cite or reference Exhibit 2025,
`
`
`
`
`4
`
`
`
`
`
`
`but instead pertain to Petitioner’s non-infringement defenses 2 and/or ANDA
`
`product. See, e.g., Preliminary Response at 5, 7, 34, 36, 51.3
`
`Petitioner understands that the rules promulgated by the USPTO “aim to
`
`strike a balance between the public’s interest in maintaining a complete and
`
`understandable file history and the parties’ interest in protecting truly sensitive
`
`information.” Office Trial Practice Guide, 77 Fed. Reg. 48,756, 48,760 (Aug. 14,
`
`2012). Petitioner contends that its redactions—constituting only portions of three
`
`sentences—are minimal and are far less than those proposed by Patent Owner in its
`
`Motion to Seal (Paper 9). Even with Petitioner’s proposed redactions the public
`
`will be left with a complete and understandable file history, only being unaware of
`
`the distribution of ingredient component in Petitioner’s ANDA product and details
`
`
`2 Indeed, Patent Owner makes assertions regarding Petitioner’s non-
`
`infringement contentions and arguments from the related District Court action. See
`
`id. at 5-6, 36. By their very nature, Petitioner’s non-infringement contentions and
`
`defenses are based on Petitioner’s actual ANDA product.
`
`3 Petitioner reserves the right to respond to Patent Owner’s Motion to Seal
`
`(Paper 9) in accordance with 37 C.F.R. § 42.25.
`
`
`
`
`5
`
`
`
`
`
`
`about Petitioner’s non-infringement defenses.4 Sandoz, Inc, IPR2015-00005, Paper
`
`21 at 4 (PTAB Apr. 24, 2014) (“The redactions to the Petitioner’s Reply appear to
`
`be limited to isolated passages that consist entirely of confidential commercial
`
`information. The redactions made to the Petitioner’s Reply would not inhibit a
`
`reader’s understanding of the substance of the Petitioner’s position.”). Petitioner
`
`contends that such information would not impede the public’s understanding of
`
`Patent Owner’s Preliminary Response and strikes the appropriate balance between
`
`the public’s interest and Petitioner’s interest in protecting its confidential
`
`information.
`
`
`4 Indeed, coupled with the statements in this paper, the public will
`
`understand what the redacted information generally relates to, left only without
`
`information about the distribution of ingredient component in Petitioner’s ANDA
`
`product.
`
`
`
`
`6
`
`
`
`
`
`
`V. Conclusion
`
`
`
`For the foregoing reasons, Petitioner respectfully requests that the Board
`
`grant the instant Motion to Seal Patent Owner’s Preliminary Response.
`
`Date: July 13, 2017
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`Alston & Bird LLP
`
`By: /Jitendra Malik/
`
`Jitendra Malik, Ph.D.
`Reg. No. 55823
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`jitty.malik@alston.com
`
`Lead Counsel for Petitioner
`
`
`
`
`7
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4) and 42.105, the undersigned
`
`certifies that on the 13th day of July, 2017, a complete copy of the foregoing
`
`Petitioner’s Motion to Seal was served on counsel of record for the Patent Owner:
`
`Gary N. Frischling (Reg. No. 35,515)
`gfrischling@irell.com
`
`Yite John Lu (Reg. No. 63,158)
`yjlu@irell.com
`
`CosmoIPR@irell.com
`
`
`
`
`
`Respectfully submitted,
`
`Alston & Bird LLP
`
`By: /Jitendra Malik/
`
`Jitendra Malik, Ph.D.
`Reg. No. 55823
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`jitty.malik@alston.com
`
`Lead Counsel for Petitioner
`
`
`1
`
`